InvestorNewsBreaks – Annovis Bio Inc. (NYSE: ANVS) Closes $10 Million Offering To Fund Phase 3 Milestones Through 2027
April 10, 2026
Annovis Bio (NYSE: ANVS), a Phase 3 clinical-stage biotechnology company developing buntanetap for neurodegenerative diseases including Alzheimer’s disease and Parkinson’s disease, announced the closing of an underwritten public offering raising approximately $10 million in gross proceeds. Combined with existing cash and a recent $1.5 million investment from Board Chair Michael Hoffman, the financing is expected […]
InvestorNewsBreaks – Annovis Bio Inc. (NYSE: ANVS) Highlights Buntanetap Development in The Scientist Publication
March 31, 2026
Annovis Bio (NYSE: ANVS) announced the publication of an article in The Scientist detailing the discovery and development of its lead drug candidate buntanetap, as the company advances ongoing Phase 3 and extension studies in Alzheimer’s disease and Parkinson’s disease. The company said the article provides historical and scientific context for buntanetap’s progression, with current […]
InvestorNewsBreaks – Annovis Bio Inc. (NYSE: ANVS) Partners With NeuroRPM To Integrate AI Platform In Parkinson Study
March 19, 2026
Annovis Bio (NYSE: ANVS), a Phase 3 clinical-stage biotechnology company, announced a partnership with NeuroRPM to implement an FDA-cleared AI platform in its ongoing Parkinson’s disease study, enabling real-time monitoring of symptoms such as bradykinesia, tremor and dyskinesia through wearable and mobile technology, with the data serving as digital biomarkers to enhance disease tracking, support […]
InvestorNewsBreaks – Annovis Bio Inc. (NYSE: ANVS) Receives Positive DSMB Recommendation to Continue Phase 3 Alzheimer’s Trial
February 12, 2026
Annovis Bio (NYSE: ANVS) announced that an independent Data and Safety Monitoring Board has issued a positive recommendation supporting continuation of its ongoing pivotal Phase 3 Alzheimer’s disease clinical trial of buntanetap without modification following a 6-month safety review. The DSMB found no safety concerns after evaluating unmasked data, with safety outcomes in Alzheimer’s patients consistent with those observed in […]
InvestorNewsBreaks – Annovis Bio Inc. (NYSE: ANVS) to Launch Open-Label Extension Study of Buntanetap in Parkinson Disease
December 19, 2025
Annovis Bio (NYSE: ANVS) announced it will initiate an open-label extension study in January 2026 to further evaluate the long-term safety and efficacy of buntanetap in patients with Parkinson disease. The study will provide continued access to buntanetap for participants from prior clinical trials while enabling extended monitoring of safety outcomes, sustained effects on motor and cognitive function, and the collection of biomarker […]
InvestorNewsBreaks – Annovis Bio Inc. (NYSE: ANVS) Schedules Corporate Update Webinar and Live Q&A Session
December 16, 2025
Annovis Bio (NYSE: ANVS), a late-stage clinical drug platform company developing therapies for neurodegenerative diseases including Alzheimer disease and Parkinson disease, will host a corporate update webinar followed by a live question-and-answer session. The webinar will feature President and Chief Executive Officer Maria Maccecchini, Ph.D., who will provide an overview of recent company progress, ongoing […]
InvestorNewsBreaks – Annovis Bio Inc. (NYSE: ANVS) to Present New Buntanetap Findings at Parkinson Study Group Annual Meeting
December 3, 2025
Annovis Bio (NYSE: ANVS), a late-stage clinical drug platform company developing therapies for neurodegenerative diseases including Alzheimer’s disease and Parkinson’s disease, said it will present at the 2025 Annual Meeting of the Parkinson Study Group, held Dec. 4–6 in San Diego. The presentation will expand on recent Phase 3 Parkinson’s biomarker results showing that patients […]
InvestorNewsBreaks – Annovis Bio Inc. (NYSE: ANVS) Secures FDA Type C Meeting to Advance Parkinson’s Disease Dementia Program
November 18, 2025
Annovis Bio (NYSE: ANVS) a late-stage clinical drug platform company developing therapies for neurodegenerative diseases including Alzheimer’s and Parkinson’s, announced that the FDA has scheduled a Type C meeting in January 2026 to discuss the clinical pathway for buntanetap in Parkinson’s disease dementia. The Company also reaffirmed continued progress in its Phase 3 Alzheimer’s trial, […]
InvestorNewsBreaks – Annovis Bio Inc. (NYSE: ANVS) Reports New Data Showing Buntanetap Reverses Cognitive Decline in Parkinson’s Patients With Amyloid Co-Pathology
November 17, 2025
Annovis Bio (NYSE: ANVS) released new findings from its Phase 3 early Parkinson’s disease study showing that buntanetap halted cognitive decline across all patients and delivered the strongest benefit in those with mild dementia and amyloid co-pathology, a group representing about 25% of the study population. These patients typically experience faster cognitive deterioration, but treatment […]
InvestorNewsBreaks – Annovis Bio Inc. (NYSE: ANVS) Reports Major Clinical and Corporate Milestones as Phase 3 Alzheimer’s Trial Advances Toward Completion
November 12, 2025
Annovis Bio (NYSE: ANVS), a late-stage clinical drug platform company developing therapies for neurodegenerative diseases including Alzheimer’s and Parkinson’s, reported significant third quarter 2025 progress, led by full activation of all 84 sites in its pivotal Phase 3 Alzheimer’s study (NCT06709014) and steady enrollment across the U.S. The company also announced promising biomarker data from […]
InvestorNewsBreaks – Annovis Bio Inc. (NYSE: ANVS) Completes Site Activation and Marks First Patient Completions in Pivotal Phase 3 Alzheimer’s Trial
November 6, 2025
Annovis Bio (NYSE: ANVS), a late-stage clinical drug platform company developing therapies for neurodegenerative diseases including Alzheimer’s and Parkinson’s, announced that all 84 U.S. sites for its pivotal Phase 3 trial in early Alzheimer’s disease are now fully activated and enrolling, with most already treating patients. The first group of participants has completed the 6-month […]
InvestorNewsBreaks – Annovis Bio Inc. (NYSE: ANVS) Announces $3.4 Million Registered Direct Offering
October 27, 2025
Annovis Bio (NYSE: ANVS), a late-stage clinical drug platform company developing therapies for neurodegenerative diseases including Alzheimer’s and Parkinson’s, entered definitive agreements for a registered direct offering of 1,670,732 shares of common stock at $2.05 per share, reflecting the Oct. 24 closing price. The $3.4 million offering, led by H.C. Wainwright & Co. as exclusive […]
InvestorNewsBreaks – Annovis Bio Inc. (NYSE: ANVS) Closes $6 Million Registered Direct Offering
October 16, 2025
Annovis Bio (NYSE: ANVS), a late-stage clinical drug platform company developing therapies for neurodegenerative diseases including Alzheimer’s and Parkinson’s, closed its previously announced registered direct offering of 4 million shares of common stock (or pre-funded warrants) at $1.50 per share. H.C. Wainwright & Co. served as exclusive placement agent. Gross proceeds totaled approximately $6 million […]
InvestorNewsBreaks – Annovis Bio Inc. (NYSE: ANVS) Reports Biomarker Data Showing Buntanetap Reduces Inflammation and Strengthens Neuronal Health in Alzheimer’s Patients
October 9, 2025
Annovis Bio (NYSE: ANVS), a late-stage clinical drug platform company developing therapies for neurodegenerative diseases including Alzheimer’s and Parkinson’s, announced new results showing that buntanetap reduced key inflammatory biomarkers and improved neuronal integrity in Alzheimer’s patients. Data from the Phase 2/3 study demonstrated lower levels of IL-5, IL-6, S100A12, IFN-γ, and IGF1R in treated patients […]
InvestorNewsBreaks – Annovis Bio Inc. (NYSE: ANVS) Appoints Mark Guerin as Chief Financial Officer
September 25, 2025
Annovis Bio (NYSE: ANVS), a late-stage clinical drug platform company developing therapies for neurodegenerative diseases, announced the appointment of Mark Guerin, CPA, CMA, CFM, as Chief Financial Officer to help guide the Company as its lead drug candidate, buntanetap, advances through late-stage trials. Guerin previously served as CFO of Onconova Therapeutics, now Traws Pharma (NASDAQ: […]
InvestorNewsBreaks – Annovis Bio Inc. (NYSE: ANVS) to Present at H.C. Wainwright Global Investment Conference
September 2, 2025
Annovis Bio (NYSE: ANVS) announced that CEO Maria Maccecchini, Ph.D., will present at the H.C. Wainwright 27th Annual Global Investment Conference, taking place Sept. 8-10, 2025, at the Lotte New York Palace Hotel in New York City. To view the full press release, visit https://ibn.fm/bX1aJ About Annovis Bio Inc. Headquartered in Malvern, Pennsylvania, Annovis is […]
InvestorNewsBreaks – Annovis Bio Inc. (NYSE: ANVS) Advances Phase 3 Alzheimer’s Trial, Strengthens IP Portfolio, Reports Q2 2025 Results
August 13, 2025
Annovis Bio (NYSE: ANVS), a late-stage clinical drug platform company developing therapies for neurodegenerative diseases, announced second-quarter 2025 results and corporate updates. The pivotal Phase 3 trial in early Alzheimer’s disease (NCT06709014) now includes 76 secured U.S. sites, with 46 actively enrolling, 38 patients dosed, and nearly 200 in screening. Enrollment is progressing on schedule […]
InvestorNewsBreaks – Annovis Bio Inc. (NYSE: ANVS) Secures Full Patent Coverage for New Crystalline Form of Buntanetap
August 7, 2025
Annovis Bio (NYSE: ANVS), a late-stage clinical company advancing treatments for neurodegenerative diseases, announced the successful transfer and expansion of its intellectual property to fully cover both the original and new crystalline forms of buntanetap. The comprehensive patent portfolio, now protected through 2046, includes composition of matter, mechanism of action, and use in multiple indications. […]
InvestorNewsBreaks – Annovis Bio Inc. (NYSE: ANVS) to Present Alzheimer’s Advances at AAIC 2025 in Toronto
June 26, 2025
Annovis Bio (NYSE: ANVS), a late-stage clinical company focused on therapies for neurodegenerative diseases, announced its leadership will attend the Alzheimer’s Association International Conference (AAIC) from July 27–31, 2025, in Toronto. The company will present four scientific posters detailing progress on its Alzheimer’s clinical program and pharmacokinetic data for its lead candidate, buntanetap. Topics include […]
InvestorNewsBreaks – Annovis Bio Inc. (NYSE: ANVS) Gains 18-Month NYSE Compliance Window
June 20, 2025
Annovis Bio (NYSE: ANVS), a clinical-stage platform company developing therapies for neurodegenerative diseases including Alzheimer’s and Parkinson’s, has received formal acceptance from the New York Stock Exchange of its compliance plan addressing minimum market capitalization and stockholders’ equity requirements. The NYSE granted the company an 18-month window, beginning March 26, 2025, to regain compliance. During […]
InvestorNewsBreaks – Annovis Bio Inc. (NYSE: ANVS) to Host Webcast With CEO to Share Updates on Alzheimer’s and Parkinson’s Programs
June 5, 2025
Annovis Bio (NYSE: ANVS) announced it will host a live webcast on June 24, 2025, at 4:30 PM EDT, featuring President and CEO Maria Maccecchini, Ph.D. The event will provide updates on the company’s pivotal Phase 3 trial for early Alzheimer’s disease, recent FDA feedback on its Parkinson’s disease program, and other key initiatives. The […]
InvestorNewsBreaks – Annovis Bio Inc. (NYSE: ANVS) Advances Phase 3 Alzheimer’s Trial and Expands Conference Presence in Q1
May 14, 2025
Annovis Bio (NYSE: ANVS) initiated its pivotal Phase 3 clinical trial in early Alzheimer’s disease during Q1 2025, with enrollment now underway for up to 760 participants to assess buntanetap’s symptomatic and disease-modifying effects over 18 months. The company also secured a new U.S. patent for buntanetap and participated in several key scientific and investor […]
InvestorNewsBreaks – Annovis Bio Inc. (NYSE: ANVS) Appoints Hui Liu as Director of Biostatistics
April 29, 2025
Annovis Bio (NYSE: ANVS), announced the appointment of Hui Liu as Director of Biostatistics as the company advances its pivotal Phase 3 Alzheimer’s disease trial. Liu brings over 19 years of experience in clinical trial design, analysis and regulatory submission support across multiple therapeutic areas. Annovis stated that Liu’s expertise will help reinforce the scientific […]
InvestorNewsBreaks – Annovis Bio Inc. (NYSE: ANVS) Receives NYSE Noncompliance Notice Over Market Cap and Equity Levels
March 28, 2025
Annovis Bio (NYSE: ANVS), a late-stage clinical drug platform company focused on therapies for neurodegenerative diseases, disclosed it received a noncompliance notice from the New York Stock Exchange on March 26, 2025, for falling short of continued listing standards under Section 802.01B. The notice stated that the company’s average global market capitalization over a 30-day […]
InvestorNewsBreaks – Annovis Bio Inc. (NYSE: ANVS) to Present Late-Stage Alzheimer’s and Parkinson’s Data at AD/PD 2025
March 25, 2025
Annovis Bio (NYSE: ANVS), a clinical-stage drug platform company focused on neurodegenerative diseases, will present key data from its Phase 3 Parkinson’s and Phase 2/3 Alzheimer’s studies at the AD/PD™ 2025 conference in Vienna from April 1–5. Presentations will highlight buntanetap’s impact on cognition and motor function in early Parkinson’s patients, and its advantages for […]
InvestorNewsBreaks – Annovis Bio Inc. (NYSE: ANVS) Advances Alzheimer’s and Parkinson’s Pipeline, Launches Pivotal Phase 3 Trial
March 24, 2025
Annovis Bio (NYSE: ANVS), a late-stage clinical drug platform company, reported fourth quarter and full year 2024 results, highlighting major milestones in its buntanetap program for Alzheimer’s and Parkinson’s disease. The company completed two key trials last year, showing cognitive and motor improvements, leading to FDA clearance for a pivotal Phase 3 trial in early […]
InvestorNewsBreaks – Annovis Bio Inc. (NYSE: ANVS) to Present at Alzheimer’s & Parkinson’s Drug Development Summit
March 11, 2025
Annovis Bio (NYSE: ANVS), a late-stage clinical drug platform company focused on neurodegenerative diseases, will participate in the 13th Alzheimer’s & Parkinson’s Drug Development Summit from March 18-20 in Boston. CEO Maria Maccecchini, Ph.D., will present Phase III data on buntanetap and discuss a holistic approach to targeting neurotoxic proteins on March 19. Annovis will […]
InvestorNewsBreaks – Annovis Bio Inc. (NYSE: ANVS) to Host Patient Forum on Alzheimer’s and Parkinson’s Trials
February 19, 2025
Annovis Bio (NYSE: ANVS) will host a live webcast on Feb. 27, 2025, at 4:30 p.m. EST, where CEO Maria Maccecchini, Ph.D., will answer questions from patients, caregivers, and families regarding the company’s clinical trials and future plans. The forum will provide updates on the ongoing Phase 3 Alzheimer’s disease trial, plans for the Phase […]
Annovis to Host Patients’ Live Forum on February 27, 2025
February 19, 2025
MALVERN, Pa., Feb. 19, 2025 (GLOBE NEWSWIRE) — via IBN – Annovis Bio, Inc. (NYSE: ANVS) (“Annovis” or the “Company”), a clinical-stage drug platform company developing novel therapies for neurodegenerative diseases such as Alzheimer’s disease (AD) and Parkinson’s disease (PD), will host a live webcast where CEO Maria Maccecchini, Ph.D., will answer questions from patients, […]
InvestorNewsBreaks – Annovis Bio Inc. (NYSE: ANVS) CEO to Present at Oppenheimer Healthcare Conference
February 7, 2025
Annovis Bio (NYSE: ANVS) a late-stage clinical drug platform company developing therapies for neurodegenerative diseases, announced that CEO Maria Maccecchini, Ph.D., will present at Oppenheimer’s 35th Annual Healthcare Life Sciences Conference on Feb. 11, 2025, from 12:40 to 1:10 p.m. ET. The virtual presentation will cover the company’s progress on its pivotal Phase 3 trial […]
Annovis to Present at Oppenheimer’s 35th Annual Healthcare Life Sciences Conference
February 7, 2025
MALVERN, Pa., Feb. 07, 2025 (GLOBE NEWSWIRE) — via IBN – Annovis Bio Inc. (NYSE: ANVS) (“Annovis” or the “Company”), a late-stage clinical drug platform company pioneering transformative therapies for neurodegenerative diseases such as Alzheimer’s disease (AD) and Parkinson’s disease (PD), today announced that its CEO, Maria Maccecchini, Ph.D., will present at the Oppenheimer’s 35th […]
InvestorNewsBreaks – Annovis Bio Inc. (NYSE: ANVS) Enrolls First Patients in Phase 3 Alzheimer’s Trial
February 6, 2025
Annovis Bio (NYSE: ANVS) announced that the first two patients have been enrolled in its pivotal Phase 3 trial evaluating buntanetap for early Alzheimer’s disease. The randomized, placebo-controlled study will assess the drug’s symptomatic and potential disease-modifying effects over 18 months. Following positive Phase 2/3 results, the trial received FDA approval and aims to enroll […]
Annovis Bio, Inc. Announces Closing of $21 Million Public Offering
February 6, 2025
MALVERN, PA, Feb. 04, 2025 (GLOBE NEWSWIRE) — via IBN – Annovis Bio, Inc. (NYSE: ANVS) (“Annovis” or the “Company”), a late-stage clinical drug platform company pioneering transformative therapies for neurodegenerative diseases such as Alzheimer’s disease (AD) and Parkinson’s disease (PD), today announced the closing of its previously announced underwritten public offering of 5,250,000 shares of […]
InvestorNewsBreaks – Annovis Bio Inc. (NYSE: ANVS) Closes $21M Public Offering to Advance Alzheimer’s Drug Development
February 5, 2025
Annovis Bio (NYSE: ANVS), a late-stage clinical drug company focused on neurodegenerative diseases, announced the closing of its underwritten public offering, raising $21 million in gross proceeds. The offering included 5.25 million shares of common stock and warrants at a combined price of $4.00 per share, with warrants exercisable at $5.00 per share for five […]
Annovis Announces First Patients Entered into Pivotal Phase 3 Study of Buntanetap for Early Alzheimer’s Disease
February 5, 2025
MALVERN, Pa., Feb. 05, 2025 (GLOBE NEWSWIRE) — via IBN – Annovis Bio Inc. (NYSE: ANVS) (“Annovis” or the “Company”), a late-stage clinical drug platform company pioneering transformative therapies for neurodegenerative diseases such as Alzheimer’s disease (AD) and Parkinson’s disease (PD), today announced that the first two patients have been entered into the pivotal Phase […]
InvestorNewsBreaks – Annovis Bio Inc. (NYSE: ANVS) Prices $21 Million Public Offering
February 3, 2025
Annovis Bio (NYSE: ANVS), a late-stage clinical drug platform company developing treatments for neurodegenerative diseases, has priced an underwritten public offering of 5.25 million shares of common stock and warrants at a combined price of $4 per share. The warrants, exercisable at $5 per share for five years, are expected to generate gross proceeds of […]
Annovis Bio, Inc. Announces Pricing of $21 Million Public Offering
February 3, 2025
MALVERN, Pa., Feb. 03, 2025 (GLOBE NEWSWIRE) — via IBN – Annovis Bio, Inc. (NYSE: ANVS) (“Annovis” or the “Company”), a late-stage clinical drug platform company pioneering transformative therapies for neurodegenerative diseases such as Alzheimer’s disease (AD) and Parkinson’s disease (PD), today announced the pricing of an underwritten public offering of 5,250,000 shares of common […]
InvestorNewsBreaks – Annovis Bio Inc. (NYSE: ANVS) Secures U.S. Patent for Acute Neurodegenerative Treatment
January 14, 2025
Annovis Bio (NYSE: ANVS), a late-stage clinical drug platform company, has received a U.S. patent for methods using buntanetap to treat and prevent acute brain and nerve injuries. The patent, issued on Jan. 2, 2025 (US-2025-0000846-A1), covers buntanetap’s ability to reduce neurotoxicity and mitigate neurodegenerative processes in conditions such as stroke, ischemia, traumatic brain injury, […]
Annovis Granted U.S. Patent for Treatment and Prevention of Acute Brain or Nerve Injuries Securing Global Protection
January 13, 2025
MALVERN, Pa, Jan. 14, 2025 (GLOBE NEWSWIRE) — Annovis Bio Inc. (NYSE: ANVS) (“Annovis” or the “Company”), a late-stage clinical drug platform company pioneering transformative therapies for neurodegenerative diseases such as Alzheimer’s disease (AD) and Parkinson’s disease (PD), today announced it was granted the U.S. patent covering methods for the treatment and prevention of acute […]
InvestorNewsBreaks – Annovis Bio Inc. (NYSE: ANVS) Announces Streamlined Pathway to Advance Buntanetap for AD
January 7, 2025
Annovis Bio (NYSE: ANVS), a late-stage clinical drug platform company pioneering transformative therapies for neurodegenerative diseases such as Alzheimer’s disease (“AD”) and Parkinson’s disease (“PD”), today announced that the FDA has accepted an updated protocol for the pivotal Phase 3 AD study, which is slated to begin in January 2025. In October 2024, the FDA […]